Quintiles selects BRANY as U.S. Prime site
BRANY (Biomedical Research Alliance of New York) has been designated a Quintiles Prime Site. The designation will advance BRANY’s participation in clinical trials by providing improved access to new industry-sponsored clinical trials.
“BRANY is committed to excellence in clinical research and improving patient care,” said Kimberly Irvine, executive vice president of operations at BRANY. “This alliance will provide our leading investigators and hospitals with significant opportunities to access industry-sponsored clinical trials. We are excited to be working with Quintiles to bring new clinical trials to our sites and patients.”
BRANY’s Smart Start 60 increases efficiencies and sustainability among their community and academic study sites to expedite clinical research timelines. These efficiencies translate to real-life benefits as clinical trials are concluded on or ahead of schedule to advance treatments for unmet medical needs in a cost-effective way that does not jeopardize the quality standards of the of research.
“We have been working with BRANY for 14 years and are continuously impressed with the calibre of their investigator network and the quality of their research,” said Lindy Jones, senior vice president, integrated site services, Quintiles. “BRANY consistently sets and meets aggressive start-up timelines. They are able to conduct studies in both the hospital and community setting broadening opportunities for patients to participate in studies. We welcome BRANY as the newest Prime Site and look forward to continued success together.”